Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis

To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the impact on the objective response rate (ORR), survival rate and grade 3/4 adverse events. Of the 2,056 patients included from 26...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiyin, Xu, Jin, Hua, Jie, Liu, Jiang, Liang, Chen, Meng, Qingcai, Ni, Quanxing, Shi, Si, Yu, Xianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691695/
https://www.ncbi.nlm.nih.gov/pubmed/31413762
http://dx.doi.org/10.7150/jca.29898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691695/
https://www.ncbi.nlm.nih.gov/pubmed/31413762
http://dx.doi.org/10.7150/jca.29898

Ejemplares similares